A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Anthracyclines
- Indications Breast cancer
- Focus Therapeutic Use
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2013 New trial record